A new nanoparticle vaccine developed by MIT researchers could assist efforts to eradicate polio worldwide. The vaccine, which delivers multiple doses in just one injection, could make it easier to immunize children in remote regions of Pakistan and other countries where the disease is still found.
While the number of reported cases of polio dropped by 99 percent worldwide between 1988 and 2013, according to the Centers for Disease Control, the disease has not been completely eradicated, in part because of the difficulty in reaching children in remote areas to give them the two to four polio vaccine injections required to build up immunity.
“Having a one-shot vaccine that can elicit full protection could be very valuable in being able to achieve eradication,” says Ana Jaklenec, a research scientist at MIT’s Koch Institute for Integrative Cancer Research and one of the senior authors of the paper.
Robert Langer, the David H. Koch Institute Professor at MIT, is also a senior author of the study, which appears in the Proceedings of the National Academy of Sciences the week of May 21. Stephany Tzeng, a former MIT postdoc who is now a research associate at Johns Hopkins University School of Medicine, is the paper’s lead author.
“We are very excited about the approaches and results in this paper, which I hope will someday lead to better vaccines for patients around the world,” Langer says.
There are no drugs against poliovirus, and in about 1 percent of cases, it enters the nervous system, where it can cause paralysis. The first polio vaccine, also called the Salk vaccine, was developed in the 1950s. This vaccine consists of an inactivated version of the virus, which is usually given as a series of two to four injections, beginning at 2 months of age. In 1961, an oral vaccine was developed, which offers some protection with only one dose but is more effective with two to three doses.
The oral vaccine, which consists of a virus that has reduced virulence but is still viable, has been phased out in most countries because in very rare cases, it can mutate to a virulent form and cause infection. It is still used in some developing countries, however, because it is easier to administer the drops than to reach children for multiple injections of the Salk vaccine.
For polio eradication efforts to succeed, the oral vaccine must be completely phased out, to eliminate the chance of the virus reactivating in an immunized person. Several years ago, Langer’s lab received funding from the Bill and Melinda Gates Foundation to try to develop an injectable vaccine that could be given just once but carry multiple doses.
“The goal is to ensure that everyone globally is immunized,” Jaklenec says. “Children in some of these hard-to-reach developing world locations tend to not get the full series of shots necessary for protection.”
To create a single-injection vaccine, the MIT team encapsulated the inactivated polio vaccine in a biodegradable polymer known as PLGA. This polymer can be designed to degrade after a certain period of time, allowing the researchers to control when the vaccine is released.
“There’s always a little bit of vaccine that’s left on the surface or very close to the surface of the particle, and as soon as we put it in the body, whatever is at the surface can just diffuse away. That’s the initial burst,” Tzeng says. “Then the particles sit at the injection site and over time, as the polymer degrades, they release the vaccine in bursts at defined time points, based on the degradation rate of the polymer.”
The researchers had to overcome one major obstacle that has stymied previous efforts to use PLGA for polio vaccine delivery: The polymer breaks down into byproducts called glycolic acid and lactic acid, and these acids can harm the virus so that it no longer provokes the right kind of antibody response.
To prevent this from happening, the MIT team added positively charged polymers to their particles. These polymers act as “proton sponges,” sopping up extra protons and making the environment less acidic, allowing the virus to remain stable in the body.
“I think the beauty of the paper is that the traditional microparticle formulation design principles for antigen stabilization are applicable to the delivery of a very complex antigen system. Single dose vaccination for developing world applications is a Holy Grail, and they are getting close,” says David Putnam, a professor of biomedical engineering and chemical and biomolecular engineering at Cornell University who was not involved in the research.
In the PNAS study, the researchers designed particles that would deliver an initial burst at the time of injection, followed by a second release about 25 days later. They injected the particles into rats, then sent blood samples from the immunized rats to the Centers for Disease Control for testing. Those studies revealed that the blood samples from rats immunized with the single-injection particle vaccine had an antibody response against poliovirus just as strong as, or stronger than, antibodies from rats that received two injections of Salk polio vaccine.
To deliver more than two doses, the researchers say they could design particles that release vaccine at injection and one month later, and mix them with particles that release at injection and two months later, resulting in three overall doses, each a month apart. The polymers that the researchers used in the vaccines are already FDA-approved for use in humans, so they hope to soon be able to test the vaccines in clinical trials.
Learn more: A single-injection vaccine for the polio virus
The Latest on: Nanoparticle vaccine
via Google News
The Latest on: Nanoparticle vaccine
- New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy on February 19, 2019 at 12:43 pm
SNAs are ball-like forms of DNA and RNA arranged on the surface of a nanoparticle ... and more recently, as vaccines that stimulate the body's own immune system to treat diseases, including ... […]
- Emergex to drive vaccine development with R&D facility and new hire on February 19, 2019 at 2:30 am
A nanotechnology expert, Dr Williams has extensive experience in the field of gold nanoparticle development and has been ... "We are looking forward to working together to effectively progress our vac... […]
- Emergex Secures State-of-the-Art R&D Facility and Hires a Chief Scientific Officer to Drive Development of Its Vaccines on February 18, 2019 at 1:00 am
This gives the Company overall internal control of all its vaccine development programs. Furthermore, key personnel at the site, who are highly experienced in the design, production and development of ... […]
- Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 on February 12, 2019 at 1:21 pm
It is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology. “The... […]
- HIV glycans and nanoparticle vaccines on February 7, 2019 at 1:37 pm
Synthetic nanoparticles have attracted widespread interest for vaccine design, but how the immune system generates a response to multimeric nanoparticles remains unclear. Tokatlian et al. studied immu... […]
- A sweeter approach to vaccine design on February 7, 2019 at 12:07 pm
Engineering of nanoparticles with a dense array of glycans enables recognition by MBL, facilitating transport to the B cell zone and increasing the magnitude and quality of the humoral immune response ... […]
- Sen. Blumenthal pushes for universal flu vaccine on February 1, 2019 at 3:05 am
"But a universal flu vaccine would be effective against all the strains and ... There are a lot of approaches they are taking, one involves nanoparticles, one involves DNA. They're not there yet, but ... […]
- Novel Nanoparticle Vaccine Protects against Influenza A Virus in Animal Study on August 1, 2018 at 2:02 am
Dr. Bao-Zhong Wang of the Institute for Biomedical Sciences at Georgia State University and colleagues have developed an experimental nanoparticle vaccine against influenza A virus that seems to work ... […]
- Nanoparticle vaccine made with peptides effective against influenza virus, study finds on July 30, 2018 at 12:19 pm
A new, double-layered nanoparticle vaccine made with peptides has been found to effectively protect mice against influenza A virus, according to a study led by Georgia State University. Influenza, a c... […]
via Bing News